Seth Blackley Sells 15,000 Shares of Evolent Health Inc (EVH) Stock

Evolent Health Inc (NYSE:EVH) President Seth Blackley sold 15,000 shares of the firm’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the transaction, the president now owns 760,944 shares of the company’s stock, valued at $19,023,600. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Seth Blackley also recently made the following trade(s):

  • On Monday, April 17th, Seth Blackley sold 15,000 shares of Evolent Health stock. The shares were sold at an average price of $21.48, for a total value of $322,200.00.
  • On Thursday, March 30th, Seth Blackley sold 15,000 shares of Evolent Health stock. The shares were sold at an average price of $21.19, for a total value of $317,850.00.

Shares of Evolent Health Inc (NYSE:EVH) traded up 1.398% during trading on Friday, hitting $23.575. The stock had a trading volume of 283,670 shares. Evolent Health Inc has a 12-month low of $11.11 and a 12-month high of $26.84. The firm’s market cap is $1.36 billion. The stock has a 50-day moving average of $22.92 and a 200 day moving average of $19.66.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.11. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $104.38 million. During the same quarter last year, the business posted ($0.16) EPS. Evolent Health’s quarterly revenue was up 116.2% compared to the same quarter last year. On average, analysts predict that Evolent Health Inc will post ($0.41) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

ILLEGAL ACTIVITY WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/05/19/seth-blackley-sells-15000-shares-of-evolent-health-inc-evh-stock.html.

Several large investors have recently bought and sold shares of EVH. US Bancorp DE raised its stake in Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after buying an additional 19 shares during the period. American International Group Inc. raised its stake in Evolent Health by 7.5% in the first quarter. American International Group Inc. now owns 9,403 shares of the technology company’s stock worth $210,000 after buying an additional 653 shares during the period. White Pine Investment CO raised its stake in Evolent Health by 0.8% in the first quarter. White Pine Investment CO now owns 97,470 shares of the technology company’s stock worth $2,174,000 after buying an additional 750 shares during the period. UBS Asset Management Americas Inc. raised its stake in Evolent Health by 5.6% in the third quarter. UBS Asset Management Americas Inc. now owns 15,000 shares of the technology company’s stock worth $369,000 after buying an additional 800 shares during the period. Finally, Teachers Advisors LLC raised its stake in Evolent Health by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 25,119 shares of the technology company’s stock worth $372,000 after buying an additional 1,211 shares during the period. Institutional investors and hedge funds own 52.14% of the company’s stock.

A number of equities analysts recently commented on EVH shares. Zacks Investment Research upgraded Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a report on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and set a $28.00 target price on shares of Evolent Health in a report on Thursday, April 13th. Cantor Fitzgerald restated a “buy” rating and set a $26.00 target price on shares of Evolent Health in a report on Wednesday, March 1st. Leerink Swann set a $24.00 target price on Evolent Health and gave the company a “buy” rating in a report on Tuesday, February 28th. Finally, Canaccord Genuity restated a “buy” rating and set a $31.00 target price on shares of Evolent Health in a report on Friday, February 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $27.67.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply